Avacta is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and animals. The group’s Affimer technology is a revolutionary alternative to the established antibody technology which dominates the drug industry despite its limitations. Following the Placing early in the current fiscal year to fund an in-house therapeutic Affimer programme, this has added a significant new element to the
01 Aug 2016
Change in R&D accounting policy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Change in R&D accounting policy
Avacta Group PLC (AVCT:LON) | 45.5 0.5 2.2% | Mkt Cap: 163.4m
- Published:
01 Aug 2016 -
Author:
Martin Hall -
Pages:
4
Avacta is a life science company providing high quality and highly specific tools to the biopharmaceutical industry to help in the diagnosis and treatment of humans and animals. The group’s Affimer technology is a revolutionary alternative to the established antibody technology which dominates the drug industry despite its limitations. Following the Placing early in the current fiscal year to fund an in-house therapeutic Affimer programme, this has added a significant new element to the